Apollon Wealth Management LLC Lowers Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Apollon Wealth Management LLC lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 3.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,703 shares of the medical device company’s stock after selling 702 shares during the period. Apollon Wealth Management LLC’s holdings in DexCom were worth $1,377,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Dynamic Advisor Solutions LLC raised its stake in DexCom by 14.6% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 3,077 shares of the medical device company’s stock valued at $206,000 after purchasing an additional 391 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its holdings in DexCom by 290.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 3,387 shares of the medical device company’s stock valued at $227,000 after buying an additional 2,520 shares in the last quarter. Valeo Financial Advisors LLC grew its holdings in DexCom by 31.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 10,041 shares of the medical device company’s stock valued at $673,000 after buying an additional 2,424 shares in the last quarter. Gateway Investment Advisers LLC lifted its holdings in shares of DexCom by 9.1% in the third quarter. Gateway Investment Advisers LLC now owns 8,832 shares of the medical device company’s stock worth $592,000 after buying an additional 740 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of DexCom by 39.5% in the third quarter. Exchange Traded Concepts LLC now owns 12,276 shares of the medical device company’s stock worth $823,000 after buying an additional 3,474 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 0.2 %

Shares of NASDAQ DXCM opened at $88.27 on Tuesday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a 50-day simple moving average of $81.76 and a two-hundred day simple moving average of $75.11. The company has a market cap of $34.48 billion, a P/E ratio of 52.86, a PEG ratio of 2.26 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 42,342 shares of company stock valued at $3,628,069. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Citigroup lifted their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, Raymond James lowered their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.